The STARD3NL-MET gene fusion was identified in a 62-year-old female with a stage IV LADC who is a never smoker. After initial diagnosis, off-label treatment with crizotinib was started, leading to a partial response (69% reduction based on RECIST 1.1) of the primary tumor and the metastases (Fig. 1C and D). Crizotinib leads to a clinical response in patients with MET rearrangements.